BEIJING & BOSTON, January 08, 2024 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315), a global biotech company focusing on the discovery of novel antibody therapeutics, today announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. ("Radiance"), a biotechnology company specializing in developing next generation Antibody Drug Conjugates.
Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biocytogen Enters into Multi-Target Antibody Agreement With Neurocrine Biosciences streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Biocytogen Pharmaceuticals Beijing Co. Ltd. Biocytogen HKEX 02315 today announced that it has entered into an antibody evaluation and option agreement with Neurocrine Biosciences Inc.